<DOC>
	<DOCNO>NCT00532441</DOCNO>
	<brief_summary>An unmet medical need exist successful therapy patient advance hepatocellular biliary tract malignance , short live disease response chemotherapy advanced stage hepatic biliary carcinoma . Pre-clinical data show cooperative antitumor activity epidermal growth factor receptor ( EGFR ) tyrosine kinase inhibitor taxanes . The efficacy erlotinib combination docetaxel assess trial .</brief_summary>
	<brief_title>Erlotinib Combination With Docetaxel Advanced Hepatocellular Biliary Tract Carcinomas</brief_title>
	<detailed_description>Outline : This multi-center study . Patients meet eligibility criterion receive treatment follow disease progression excessive toxicity : - Erlotinib 150 mg p.o . daily day 2-7 , 9-14 , 16-28 - Docetaxel 30 mg/m2 IV 30 min weekly x 3 week day 1 , 8 , 15 Treatment cycle = 28 day Performance Status : Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 Life expectancy : At least 12 week Hematopoietic : - Absolute neutrophil count ( ANC ) &gt; 1000 mm3 - Platelet count &gt; 75,000 mm3 - Hemoglobin &gt; 8 g/dL Hepatic : - Bilirubin &lt; 2.0 x upper limit normal ( ULN ) - Transaminases ( AST , ALT ) &lt; 5.0 x ULN alkaline phosphatase &lt; 2.5 x ULN , alkaline phosphatase &lt; 5 x ULN transaminases &lt; 1.5 x ULN . - If anticoagulation : PT &lt; 4 second ULN ; INR &lt; 1.5 ; PTT &lt; 1.3 x ULN . - If therapeutic anticoagulation , patient may INR &gt; 1.5 PTT within therapeutic range ; INR monitor weekly stable . - Serum Albumin &gt; 3.0 Renal : - Creatinine clearance &gt; 60 ml/ min ( Cockcroft-Gault ) Pulmonary : - Not specify</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Histological cytological proof hepatocellular biliary tract carcinoma , amenable curative resection transplantation . Prior cancer treatment complete least 30 day prior register protocol therapy recover acute toxicity effect regimen . Patients may radiofrequency ablation , cryosurgery embolization , must document progressive disease involve lesion , least one previously untreated lesion . Patients may ≤ 2 prior chemotherapy regimen . Prior radiation therapy allow &lt; 25 % bone marrow least 30 day prior register protocol therapy . Patients biliary obstruction must percutaneous transhepatic drainage endoscopic stent placement prior start study treatment . Patients history malignancy eligible provide curatively treated demonstrate evidence recurrence cancer . Peripheral neuropathy ≤ grade 1 . Patients must agree abstain frozen fresh grapefruit grapefruit juice 5 day prior , treatment . Patients must willing use effective method contraception ( hormonal barrier method birth control ; abstinence ) treatment 12 week period thereafter . Females childbearing potential must negative pregnancy test within 7 day prior register protocol therapy . Written inform consent HIPAA authorization release personal health information . Age ≥ 18 year time consent . No previous treatment EGFR inhibitor . No treatment investigational agent within 30 day prior register protocol therapy . No symptomatic brain metastasis . A subject prior brain metastasis may consider complete treatment brain metastasis , long require corticosteroid , asymptomatic . No ChildPugh B C liver cirrhosis . No active corneal erosion history abnormal corneal sensitivity test . No history aneurysm arteriovenous malformation . No hemorrhage/bleeding event &gt; CTCAE Grade 3 within 30 day prior begin register protocol therapy . No clinically significant infection judge treat investigator . No condition impair patient 's ability swallow whole pill . No history hypersensitivity docetaxel drug formulate polysorbate 80 . Females must breastfeed . Patients avoid follow medication ineligible trial : midazolam , antimycotic agent ( ketoconazole relate compound ) , macrolide antibiotic ( erythromycin relate compound ) , nifedipine , phenobarbital , phenytoin , carbamazepine , rifampin ( induction ) antiretrovirals ( include ritonavir , saquinavir ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>